Neurogene Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $23.10
- 52-Week Range
- $15.93 – $43.66
- Market Cap
- $479.02M
- P/E (TTM)
- —
- EPS (TTM)
- -5.03
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.35
- PEG Ratio
- —
- Return on Equity
- -38.42%
- Return on Assets
- -24.37%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 19.97
- Debt/Equity
- 0.02
- Total Debt
- $7.55M
- Free Cash Flow
- $-53.29M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $126.85M
Market Snapshot
About
Neurogene Inc. is a clinical-stage biotechnology company developing gene therapies for rare neurological diseases. The company focuses on adeno-associated virus (AAV)-based gene therapies targeting conditions like Rett syndrome and other genetic neurological disorders. Neurogene uses its proprietary EXACT platform to deliver therapeutic genes directly to the central nervous system.